Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Current state of quality of life and patient-reported outcomes research

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty. / Current state of quality of life and patient-reported outcomes research. I: European journal of cancer (Oxford, England : 1990). 2019 ; Bind 121. s. 55-63.

Bibtex

@article{1f86b2d9738146cfa70fd3ef1c617266,
title = "Current state of quality of life and patient-reported outcomes research",
abstract = "The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients' experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.",
keywords = "Biomedical Research/methods, Cancer Survivors/psychology, Clinical Trials as Topic/methods, Humans, Neoplasms/epidemiology, Pain Management/methods, Patient Participation/methods, Patient Reported Outcome Measures, Psychometrics/methods, Quality of Life, Reference Standards, Surveys and Questionnaires/standards, Survivorship",
author = "Andrew Bottomley and Reijneveld, {Jaap C} and Michael Koller and Henning Flechtner and Tomaszewski, {Krzysztof A} and Eva Greimel and {5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty}",
note = "Copyright {\textcopyright} 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.",
year = "2019",
month = nov,
doi = "10.1016/j.ejca.2019.08.016",
language = "English",
volume = "121",
pages = "55--63",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",

}

RIS

TY - JOUR

T1 - Current state of quality of life and patient-reported outcomes research

AU - Bottomley, Andrew

AU - Reijneveld, Jaap C

AU - Koller, Michael

AU - Flechtner, Henning

AU - Tomaszewski, Krzysztof A

AU - Greimel, Eva

AU - 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty

N1 - Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2019/11

Y1 - 2019/11

N2 - The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients' experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.

AB - The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients' experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.

KW - Biomedical Research/methods

KW - Cancer Survivors/psychology

KW - Clinical Trials as Topic/methods

KW - Humans

KW - Neoplasms/epidemiology

KW - Pain Management/methods

KW - Patient Participation/methods

KW - Patient Reported Outcome Measures

KW - Psychometrics/methods

KW - Quality of Life

KW - Reference Standards

KW - Surveys and Questionnaires/standards

KW - Survivorship

U2 - 10.1016/j.ejca.2019.08.016

DO - 10.1016/j.ejca.2019.08.016

M3 - Journal article

C2 - 31561134

VL - 121

SP - 55

EP - 63

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

ER -

ID: 61353207